

CD5L (D-11): sc-390486

BACKGROUND

CD5L (CD5 molecule-like), also known as API6, PRO229, Sp α or SP-ALPHA, is a 347 amino acid secreted protein that belongs to the scavenger receptor cysteine-rich (SRCR) family of leukocyte regulating proteins. Expressed in bone marrow, spleen, thymus, lymph node and fetal liver, CD5L is thought to be involved in regulating the immune system via binding to peripheral monocytes and mediating their activation and overall survival. CD5L has three cysteine-rich domains and, in addition to its role in the immune system, may function to inhibit apoptosis and promote macrophage survival.

CHROMOSOMAL LOCATION

Genetic locus: CD5L (human) mapping to 1q23.1; Cd5l (mouse) mapping to 3 F1.

SOURCE

CD5L (D-11) is a mouse monoclonal antibody raised against amino acids 31-189 mapping near the N-terminus of CD5L of mouse origin.

PRODUCT

Each vial contains 200 μ g IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

CD5L (D-11) is available conjugated to agarose (sc-390486 AC), 500 μ g/0.25 ml agarose in 1 ml, for IP; to HRP (sc-390486 HRP), 200 μ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-390486 PE), fluorescein (sc-390486 FITC), Alexa Fluor® 488 (sc-390486 AF488), Alexa Fluor® 546 (sc-390486 AF546), Alexa Fluor® 594 (sc-390486 AF594) or Alexa Fluor® 647 (sc-390486 AF647), 200 μ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-390486 AF680) or Alexa Fluor® 790 (sc-390486 AF790), 200 μ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

CD5L (D-11) is recommended for detection of CD5L of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for CD5L siRNA (h): sc-88774, CD5L siRNA (m): sc-105191, CD5L shRNA Plasmid (h): sc-88774-SH, CD5L shRNA Plasmid (m): sc-105191-SH, CD5L shRNA (h) Lentiviral Particles: sc-88774-V and CD5L shRNA (m) Lentiviral Particles: sc-105191-V.


Molecular Weight of CD5L: 38 kDa.

Positive Controls: 3T3-L1 cell lysate: sc-2243, Hep G2 cell lysate: sc-2227 or CD5L (m): 293T Lysate: sc-119114.


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

DATA



CD5L (D-11): sc-390486. Western blot analysis of CD5L expression in Hep G2 (A), NIH/3T3 (B), 3T3-L1 (C), RAW 264.7 (D) and IB4 (E) whole cell lysates and human spleen tissue extract (F).



CD5L (D-11): sc-390486. Western blot analysis of CD5L expression in non-transfected 293T: sc-117752 (A), mouse CD5L transfected 293T: sc-119114 (B), mouse CD5L transfected 293T: sc-119115 (C) and Jurkat (D) whole cell lysates and rat thymus tissue extract (E). Detection reagent used: m-IgG Fc BP-HRP: sc-525409.

SELECT PRODUCT CITATIONS

- Hasegawa, H., et al. 2021. IL-23p19 and CD5 antigen-like form a possible novel heterodimeric cytokine and contribute to experimental autoimmune encephalomyelitis development. *Sci. Rep.* 11: 5266.
- Bamodu, O.A., et al. 2021. Concomitant high apoptosis inhibitor of macrophage (AIM) and low prostate-specific antigen (PSA) indicates activated T cell-mediated anticancer immunity, enhance sensitivity to pembrolizumab, and elicit good prognosis in prostate cancer. *Biomedicines* 9: 1225.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.